Deepnoid Signs Clinical Research Agreement with UGM Hospital

Published 30 Apr.2024 13:09(KST)

Deepnoid, a first-generation domestic medical AI specialist company, has signed an MOU with Indonesia's UGM (Gadjah Mada University Medical Center) for clinical research. Depending on the clinical trial results, entry and expansion into the Indonesian medical market can be anticipated.

UGM Medical Center will conduct clinical research using DEEP:AI solutions for 18 months. The targeted solutions include the real-time multi-lung disease detection and diagnosis assistance solution ‘DEEP:CHEST’, the real-time lung nodule detection and diagnosis assistance solution ‘DEEP:LUNG’, and the brain aneurysm diagnosis assistance solution ‘DEEP:NEURO’. Based on the clinical trial results, approval for the use of medical devices in Indonesia is also expected. This will enable full-scale entry into the Indonesian medical market.

Located in Yogyakarta, Indonesia, UGM Medical Center belongs to a consortium supporting seven national university hospitals across two provinces. In addition to UGM, 10 other medical institutions participate. Given the presence of major medical institutions, additional MOUs and demo installations can be anticipated.

The reason UGM Medical Center is interested in adopting DEEP:AI is due to the annually increasing number of diagnostic images. Over the past three years, the number of X-ray, MRI, and CT readings has increased by 140.8%, but the number of radiologists is only 22. The number of patients covered by public insurance is also increasing at a high rate each year, so the workload for image reading is expected to grow further.

Deepnoid, a leading domestic medical AI company, researches and develops disease image analysis solutions for diagnosis, treatment guidance, and therapy of brain aneurysms, lung diseases, and spinal diseases. With DEEP:NEURO selected as an innovative medical technology in 2023, significant sales are expected this year, and the company is actively expanding into overseas medical markets. Currently, MOUs and demo installations are also being discussed in the Philippines, Vietnam, and other countries.

Choi Woosik, CEO of Deepnoid, said, "As we make a full-scale entry into the Indonesian market, this agreement holds great significance," adding, "We will spare no effort to support this agreement so that patients visiting UGM Medical Center can receive fast and accurate diagnostic results and AI diagnostic solutions can be fully established in the Indonesian medical market."